🔄 Active Rounds May 2026

Active Funding Rounds

Medical device companies currently raising capital — 31 active rounds tracked as of May 2026

Active Rounds
31
As of May 2026
Capital Seeking
$890M
Estimated total
Avg Stage
Series C/D
Late-stage dominates
Hottest Sector
Surgical Robotics
3 simultaneous rounds

Top 10 Active Rounds

Ranked by size
iLet Bionic Pancreas
Seeking
$120M
Series E Diabetes Private 🔴 Oversubscribed
Lead Investor
Novo Holdings
Bionic pancreas scaling post-PMA approval. iLet is the first autonomous closed-loop insulin delivery system cleared by the FDA. This round fuels commercial scale-up and international expansion as demand surges from T1D patients seeking hormone-free control.
VR Surgical Robot
Seeking
$110M
Series C Surgical Robotics Private 🟠 Final Close Q2 2026
Lead Investor
General Catalyst
VR surgical robot with FDA submission imminent. Vicarious combines human-scale VR immersion with miniaturized robotics to give surgeons superhuman precision. FDA 510(k) submission expected this quarter, making this round the last before commercial launch.
Miniaturized SCS System
Seeking
$95M
Series D Neuromodulation Private 🟡 Actively Raising
Lead Investor
OrbiMed
Miniaturized SCS ahead of Gen 3 FDA submission. Nalu's pebble-sized IPG and wearable recharger remove the bulk and limitations of traditional SCS systems. Round proceeds are earmarked for the pivotal Gen 3 trial and CE Mark expansion.
Evoke Closed-Loop SCS
Seeking
$90M
Series D Neuromodulation Private 🟡 Actively Raising
Lead Investor
Cowen Healthcare
Closed-loop SCS, pre-PMA submission. Evoke is the only SCS platform with real-time sensing of evoked compound action potentials (ECAPs), enabling automatic dose adjustment. PMA submission targeted for Q3 2026 — this raise is the final runway.
OMNI Surgical System
Seeking
$65M
Series D Ophthalmology Private 🟠 Final Close
Lead Investor
NEA
OMNI 2.0 510(k) submission + commercial scale. OMNI's unique ab-interno canaloplasty addresses multiple aqueous outflow pathways simultaneously in a single device pass. OMNI 2.0 features an improved form factor and expanded label — 510(k) submission targets Q3 2026.
Machine-Vision Spine Nav
Seeking
$75M
Series C Spine Private 🟠 Final Close Expected
Lead Investor
Deerfield
Machine-vision spine navigation, rapid hospital adoption. 7D's Flash Navigation uses high-speed structured light to register in seconds — no CT or radiation required. Hospital win rate is accelerating as cost-conscious systems replace X-ray dependent alternatives.
Maestro Collaborative Robot
Seeking
$60M
Series C Surgical Robotics Private 🟡 Actively Raising
Lead Investor
Andera Partners
Maestro collaborative robot, US commercial expansion. Unlike console-based robotic systems, Maestro acts as a bedside assistant — holding and adjusting instruments on command without a dedicated surgeon console. Designed for broad hospital adoption at a fraction of da Vinci's cost.
Twist Insulin Pump
Seeking
$50M
Series B Diabetes Private 🟠 Final Close
Lead Investor
Novo Holdings
Twist pump launch capital + CGM integrations. Sequel's Twist is engineered to be the most occlusion-resistant insulin pump on the market, targeting both AID system integrations and standalone use. CGM partnerships with Dexcom and Abbott are in active negotiation.
PillBot Swallowable Robot
Seeking
$45M
Series B GI / Imaging Private 🟡 Actively Raising
Lead Investor
DCVC Bio
PillBot pivotal trial funding. Endiatx's PillBot is a swallowable, remotely-piloted gastric robot that performs GI visualization without sedation or a scope. Pivotal IDE trial enrollment begins Q3 2026 — proceeds fund site activation across 15 centers.
MyoVista wavECG
Seeking
$40M
Series B Cardiovascular Private 🟡 Actively Raising
Lead Investor
Healtheon Capital
AI wavECG cardiac diagnostics, pre-510(k). HeartSciences' MyoVista uses proprietary signal processing to detect subclinical left ventricular dysfunction — conditions standard ECGs miss entirely. 510(k) submission targeted for late 2026, with this raise covering IDE study completion and regulatory affairs.